# US 2023/0414496 A1 · Biodegradable polymer-nanoparticle based implants for ocular drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0414496 A1
- Document ID: US20230414496A1
- Status: Published application
- Kind: A1
- Application number: 18/172,360
- Filed: 2023-02-22
- Published: 2023-12-28
- Earliest claimed: 2020-05-26
- Inventors: RUPAK BANERJEE; SOUMYARWIT MANNA; JAMES AUGSBURGER
- Web page: https://patentgrep.com/patent/US20230414496A1

## CPC

- A61K 9/0051: {Ocular inserts or implants}
- A61F 9/0017: {implantable in, or in contact with, the eye, e.g. ocular inserts}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61F 2210/0004: bioabsorbable
- A61F 2240/001: Designing or manufacturing processes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

A biodegradable intravitreal implant that provide sustained release of hydrophilic therapeutic agents and methods of making and using the same to treat various ocular disorders.

## Claims

### Claim 1

A biodegradable intravitreal implant for sustained release of a hydrophilic therapeutic agent, comprising of:
a lyophilized core comprising a porous hydrophilic polymer matrix forming a swellable polymeric core;
a hydrophilic therapeutic agent distributed throughout said lyophilized core at a desired concentration;
a smooth, non-porous, bio-degradable hydrophobic polymer coating uniformly disposed about the core; and
a plurality of liposomal nanoparticles encapsulating said therapeutic agent;
wherein,
said desired concentration of said hydrophilic therapeutic agent is in a range of 10-40% by weight;
said nanoparticles are non-metallic nanoparticles; and
said biodegradable intravitreal implant is ophthalmically compatible in the eye.

### Claim 2 (depends on 1)

The implant of claim 1, wherein said hydrophilic polymer matrix comprises of a polymer selected from a group of chitosan, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, or mixtures thereof.

### Claim 3 (depends on 2)

The implant of claim 2, wherein said hydrophilic polymer matrix comprises of chitosan.

### Claim 4 (depends on 1)

The implant of claim 1, wherein said hydrophilic therapeutic agent is selected from the group consisting of methotrexate, carboplatin, cisplatin, cladribine, cyclophosphamide, cytarabine, doxorubicin, floxuridine, fluorouracil, gemcitabine hydrochloride, hydroxyurea, ifosfamide, mechlorethamine hydrochloride, mitomycin, topotecan, and hydrophilic proteins such as aflibercept, bevacizumab, ranibizumab, combinations thereof.

### Claim 5 (depends on 4)

The implant of claim 4, wherein said hydrophilic therapeutic agent is methotrexate.

### Claim 6 (depends on 1)

The implant of claim 1, wherein said hydrophilic therapeutic agent is administered in a therapeutic concentration in a range of 0.1-1.0 lpM.

### Claim 7 (depends on 1)

The implant of claim 1, wherein said hydrophobic polymer is selected from a group of polylactic acid, poly(lactic-co-glycolic) acid, polyanhydride, polycaprolactone or polyorthoesters.

### Claim 8 (depends on 7)

The implant of claim 7, wherein said hydrophobic polymer is poly(lactic-co-glycolic) acid.

### Claim 9 (depends on 8)

The implant of claim 8, wherein poly(lactic-co-glycolic) acid (PLGA) comprises of polylactic acid (PLA) and poly(glycolic) acid (PGA) in a desired ratio.

### Claim 10 (depends on 9)

The implant of claim 9, wherein said desired ratio of PLA:PGA is 50:50, 65:35 or 75:25.

### Claim 11 (depends on 1)

The implant of claim 1, wherein said non-metallic nanoparticles is selected from silica nanoparticles, graphene, nanodiamonds, fullerene, carbon nanotube, quantum dots, colloidal apatite nanoparticles or hydroxyapatite particles.

### Claim 12 (depends on 1)

The implant of claim 1, wherein said nanoparticles are in the shape of a cylinder or a sphere.

### Claim 13 (depends on 1)

The implant of claim 1, wherein said enhanced thermal therapy include activation by radio frequency, laser or ultrasound.

### Claim 14 (depends on 1)

The implant of claim 1, wherein said implant is effective to attain sustained release of said therapeutic agent in the intravitreal region of the eye for a desired release duration.

### Claim 15 (depends on 14)

The implant of claim 14, wherein the release duration is inversely proportional to the hydrophobic polymer coating thickness.

### Claim 16 (depends on 14)

The implant according to claim 14, wherein sustained release of the methotrexate is 0.2-2.0 ag/day for the release duration.

### Claim 17 (depends on 14)

The implant of claim 14, wherein the release duration is at least about one month.

### Claim 18 (depends on 14)

The implant of claim 14, wherein the release duration is at least about 8-10 weeks.

### Claim 19 (depends on 14)

The implant of claim 14, wherein the release duration is at least 3-5 months.

### Claim 20 (depends on 14)

The implant of claim 14, wherein said sustained release follows zero order kinetics for first 60% of said hydrophilic therapeutic agent and first order kinetics for subsequent 40% of said hydrophilic therapeutic agent.

### Claim 21 (depends on 14)

The implant of claim 14, wherein said sustained release of said hydrophilic therapeutic agent is effectuated by a combination of diffusion through said hydrophobic polymer coating, swelling of said polymeric core and degradation of said permeable hydrophobic coating.

### Claim 22 (depends on 14)

The implant of claim 14, wherein said sustained release of said hydrophilic therapeutic agent is initiated by activation of said non-metallic nanoparticles through enhanced thermal therapy.

### Claim 23 (depends on 1)

The implant of claim 1, wherein the core has a length of about 4 mm and a cross-sectional diameter of about 0.7 mm.

### Claim 24 (depends on 1)

The implant of claim 1, wherein the coated core has a length of about 4.2 mm and a cross-sectional diameter of about 0.9 mm.

### Claim 25

A process for making a biodegradable intravitreal implant for sustained release of a hydrophilic therapeutic agent, the process comprising:
mixing a hydrophilic therapeutic agent with a hydrophilic polymer matrix;
injecting the mixture into medical grade chemically inert flexible tubing;
lyophilizing the tubing containing the mixture to obtain hydrophilic therapeutic agent-hydrophilic polymer fibers;
extracting the hydrophilic therapeutic agent-hydrophilic polymer fibers from the tubing;
cutting the hydrophilic therapeutic agent-hydrophilic polymer fibers into a desired implant length to form a lyophilized core;
dip-coating the core into a hydrophobic coating solution, the hydrophobic coating solution having a concentration;
drying the coated core to yield a biodegradable sustained release intravitreal implant having a degradable hydrophobic polymer coating disposed about a core, the coating having a thickness and being permeable to the therapeutic agent;
injecting the hydrophilic therapeutic agent in a hydrophobic polymer shell;
double emulsification or reverse phase evaporation of lipids and/or polymers to form a lipid-based system containing the hydrophilic therapeutic agent in the core;
dissolution of lipids in an organic solvent;
dissolution of the hydrophilic active ingredient in an ionic solvent;
hydrating the lipids in the aqueous media with agitation;
evaporating the organic solvent to form lipid-based liposomal formulations; and
post-formation processing involving purification.

### Claim 26 (depends on 25)

The process of claim 25, wherein the hydrophobic coating solution concentration is proportional to the thickness of the hydrophobic polymer coating.

### Claim 27 (depends on 25)

The process of claim 25, wherein the hydrophobic coating solution concentration is 40 mg/ml.

### Claim 28 (depends on 25)

The process of claim 25, wherein said hydrophilic polymeric core comprises 10%, 25%, or 40% by weight hydrophilic therapeutic agent.

### Claim 29 (depends on 25)

The process of claim 25, wherein said organic solvents include ethanol, methanol, transcutol, iso-propanol, chloroform.

### Claim 30 (depends on 25)

The process of claim 25, wherein said ionic solvents include tetraethyl ammonium, tetra butyl ammonium, 1-butyl-2,3-dimethylimidazolium (BMMIM or DBMIM), 1-dodecyl-3-methyl-docecyl (MIM).
